The influence of common free radicals and antioxidants on development of Alzheimer's Disease

Biomedicine and Pharmacotherapy

Volumn 78, Issue , 2016, Pages 39-49

  Wojtunik Kulesza, Karolina A ^a   Oniszczuk, Anna ^a   Oniszczuk, Tomasz ^b   Waksmundzka Hajnos, Monika ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b UNIVERSITY OF LIFE SCIENCES IN LUBLIN   (Poland)

Author keywords

Alzheimer's Disease; Natural substances; Oxidative stress; Scavenging of free radicals

Indexed keywords

5 HYDROXYMETHYLFURFURAL; ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIOXIDANT; BETA SECRETASE; CATECHOLAMINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; FREE RADICAL; GAMMA GLUTAMYLCYSTEINE ETHYL ESTER; GINKGO BILOBA EXTRACT; GLUTATHIONE; PLANT EXTRACT; POLYPHENOL; QUINIC ACID; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; UBIDECARENONE; URIC ACID;

ACANTHOPANAX; ACANTHOPANAX HENRYI; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; BERBERIS AETNENSIS; CHOLINESTERASE INHIBITION; DRUG EFFECT; ENZYME INHIBITION; GINKGO BILOBA; HUMAN; MEDICINAL PLANT; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; ANTIOXIDANTS; FREE RADICALS; HUMANS; OXIDATIVE STRESS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 84958682114     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.12.024     Document Type: Review

References (139)

1. Sivanandham V. Free radicals in health and diseases-mini review. Pharmacologyonline 2011, 1:1062-1077.
2. Sibel Pala F., Gürkan H. The role of free radicals in ethiopathogenesis of diseases. Adv. Mol. Biol. 2008, 1:1-9.
3. Lushchak V.I. Free radicals, reactive oxygen species, oxidative stress and its classification. Chem.-Biol. Interact. 2014, 224:164-175.
4. Pratap Singh R., Sharad S., Kapur S. Free radicals and oxidative stress in neurodegenerative diseases: relevance of dietary antioxidants. J. Indian Acad. Clin. Med. 2004, 5:218-225.
5. Sekler A., Jiménez J.M., Rojo L., Pastene E., Fuentes P., Slachevsky A., Maccioni R.B. Cognitive impairement and Alzheimer's disease: links with oxidative stress and cholesterol metabolism. Neuropsychiatr. Dis. Treat. 2008, 4:715-722.
6. Prvulovic D., Hampel H., Pantel J. Galantamine for Alzheimer's disease. Expert Opin. Drug Metab. Toxicol. 2010, 6:345-354.
7. Sen S., Chakraborty R., Sridhar C., Reddy Y.S.R., De B. Free radicals, antioxidants, diseases and phytomedicines: current status and future prospect. Int. J. Pharm. Sci. Rev. Res. 2010, 3:91-100.
8. Burns J.M., Cooper W.J., Ferry J.L., King D.W., DiMento B.P., McNeill K., Miller C.J., Miller W.L., Peake B.M., Rusak S.A., Rose A.L., Waite T.D. Methods for reactive oxygen species (ROS) detection in aqueous environments. Aquat. Sci. 2012, 74:683-734.
9. Valko M., Leibfritz D., Moncol J., Cronin M.T.D., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. 2007, 39:44-84.
10. Fang Y.-Z., Yang S., Wu G. Free radicals. Antioxid. Nutr. Nutr. 2002, 18:872-879.
11. Das Sarma A., Mallick A.R., Ghosh A.K. Free radicals and their role in different clinical conditions: an overview. IJPSR 2010, 3:185-192.
12. Tegeli V., Karpe P., Katve V. Importance of free radical and antioxidant on human health. IJPCBS 2014, 4:1038-1050.
13. Jomova K., Vondrakova D., Lawson M., Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol. Cell. Biol. 2010, 345:91-104.
14. Moro M., Almeida A., Bolaños J.P., Lizasoain I. Mitochondrial respiratory chain and free radical generation in stroke. Free Radic. Biol. Med. 2005, 39:1291-1304.
15. Abramov A.Y., Scorziello A., Duchen M.R. Three distinct mechanisms generate oxygen free radicals in neurons and contribute to cell death during anoxia and reoxygenation. J. Neurosci. 2007, 27:1129-1138.
16. Jomova K., Baros S., Valko M. Redox active metal-induced oxidative stress in biological systems. Transit. Metal Chem. 2012, 37:127-134.
17. Crouch P.J., Barnham K.J. Therapeutic redistribution of metal ions to treat Alzheimer's Disease. Acc. Chem. Res. 2012, 45:1604-1611.
18. Valavanidis A., Vlachogianni T., Fiotakis K. Tobacco Smoke: Involvement of reactive oxygen species and stable free radicals in mechanisms of oxidative damage, carcinogenesis and synergistic effects with other respirable particles. Int. J. Environ. Res. Public Health 2009, 6:445-462.
19. Faux S.P., Tai T., Thorne D., Xu Y., Breheny D., Gaca M. The role of oxidative stress in the biological responses of lung epithelial cells to cigarette smoke. Biomarkers 2009, 14:90-96.
20. Metta S., Basalingappa D.R., Uppala S., Mitta G. Erythrocyte antioxidant defenses against cigarette smoking in ischemic heart disease. J. Clin. Diagn. Res. 2015, 9:8-11.
21. Halliwell B. Free radicals and antioxidants-quo vadis?. Trends Pharmacol. Sci. 2011, 32:125-130.
22. Cervellati C., Romani A., Seripa D., Cremonini E., Bosi C., Magon S., Bergamini C.M., Valacchi G., Pilotto A., Zuliani G. Systemic oxidative stress and conversion to dementia of elderly patients with Mild Cognitive Impairment. BioMed. Res. Int. 2014, 1-7. ID 309507.
23. Kumar S. Free radicals and antioxidants: human and food system. Pelagia Res. Libr. 2011, 2:129-135.
24. Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2005, 4:180-183.
25. Aquilano K., Baldelli S., Ciriolo M.R. Glutathione: new roles in redox signaling for an old antioxidant. Front. Pharmacol. 2014, 5:1-12.
26. Doonan R., McElwee J.J., Matthijssens F., Walker G.A., Houthoofd K., Back P., Matscheski A., Vanfleteren J.R., Gems D. Against the oxidative damage theory of aging: superoxide dismutases protect against oxidative stress but have little or no effect on life span in Caenorhabditis elegans. Genes Dev. 2008, 22:3236-3241.
27. Almeida M.L.B., Freitas W.E., Morais P.L., Sarmento J.D., Alves R.E. Bioactive compounds and antioxidant potential fruit of Ximenia americana L. Food Chem. 2016, 192:1078-1082.
28. Bachiega P., Salgado J.M., de Carvalho J.E., Ruiz A.L., Schwarz K., Tezotto T., Morzelle M.C. Antioxidant and antiproliferative activities in different maturation stages of broccoli (Brassica oleracea Italica) biofortified with selenium. Food Chem. 2016, 190:771-776.
29. Liu J., Wang C., Wang Z., Zhang C., Lu S., Liu J. The antioxidant and free-radical scavenging activities of extract and fractions from corn silk (Zea mays L.) and related flavone glycosides. Food Chem. 2011, 126:261-269.
30. Sun T., Powers J.R., Tang J. Evaluation of the antioxidant activity of asparagus, broccoli and their juices. Food Chem. 2007, 105:101-106.
31. Praticò D. Evidence of oxidative stress in Alzheimer's Disease brain and antioxidant therapy. Ann. N.Y. Acad. Sci. 2008, 1147:70-78.
32. Padurariu M., Ciobica A., Hritcu L., Stoica B., Bild W., Stefanescu C. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neurosci. Lett. 2010, 469:6-10.
33. Reitz C., Brayne C., Mayeux R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 2011, 7:137-152.
34. Gubandru M., Margina D., Tsitsimpikou C., Goutzourelas N., Tsarouhas K., Ilie M., Tsatsakis A.M., Kouretas D. Alzheimer's disease treated patients showed different patterns for oxidative stress and inflammation markers. Food Chem. Toxicol. 2013, 61:209-214.
35. Lovell M.A., Markesbery M.A. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic. Acids Res. 2007, 35:7497-7504.
36. Butterfield D.A., Bader Lange M.L., Sultana R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. BBA-Mol. Cell. Biol. Lipids 2010, 1801:924-929.
37. Casado Á., López-Fernández M.E., Casado M.C., de La Torre R. Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer. Neurochem. Res. 2008, 33:450-458.
38. Gustaw-Rothenberg K., Kowalczuk K., Stryjecka-Zimmer M. Lipids' peroxidation markers in Alzheimer's disease and vascular dementia. Geriatr. Gerontol. Int. 2010, 10:161-166.
39. López N., Tormo C., De Blas I., Llinares I., Alom J. Oxidative stress in Alzheimer's disease and mild cognitive impairment with high sensitivity and specificity. J. Alzheimers Dis. 2013, 33:823-829.
40. Skoumalová A., Hort J. Blood markers of oxidative stress in Alzheimer's disease. J. Cell. Mol. Med. 2012, 12:2291-2300.
41. Bermejo P., Martín-Aragon S., Benedí J., Susin C., Felici E., Gil P., Ribera J.M., Villar Á.M. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment. Free Radic. Res. 2008, 42:162-170.
42. Jomova K., Baros S., Valko M. Redox active metal-induced oxidative stress in biological systems. Transition Met. Chem. 2012, 37:127-134.
43. Smith M.A., Zhu X., Tabaton M., Liu G., McKeel D.W., Cohen M.L., Wang X., Siedlak S.L., Hayashi T., Nakamura M., Nunomura A., Perry G. Increased iron and free radical generation in preclinical Alzheimer Disease and Mild Cognitive Impairment. J. Alzheimers Dis. 2010, 19:363-372.
44. da Silva G.F.Z., Ming L.-J. Metallo-ROS in Alzheimer's Disease: Oxidation of neurotransmitters by CuII-b-Amyloid and neuropathology of the disease. Angew. Chem. Int. Ed. 2007, 46:3337-3341.
45. Shan X., Chang Y., Lin C.-L.G. Messenger RNA oxidation is an early event preceding cell death and causes reduced protein expression. FASEB J. 2007, 21:2753-2764.
46. Gackowski D., Rozalski R., Siomek A., Dziaman T., Nicpon K., Klimarczyk M., Araszkiewicz A., Olinski R. Oxidative stress and oxidative DNA damage is characteristic for mixed Alzheimer disease/vascular dementia. J. Neurol. Sci. 2008, 266:57-62.
47. Ansari M.A., Scheff S.W. Oxidative stress in the progression of Alzheimer Disease in the frontal cortex. J. Neuropathol. Exp. Neurol. 2010, 69:155-167.
48. Manczak M., Anekonda T.S., Henson E., Park B.S., Quinn J., Reddy P.H. Mitochondria are a direct site of Ab accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 2006, 15:1437-1449.
49. Siedlak S.L., Casadeus G., Webber K.M., Pappolla M.A., Atwood C.S., Smith M.A., Perry G. Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease. Free Radic. Res. 2009, 43:156-164.
50. Andersen H.R., Jeune B., Nybo J.B., Andersen-Ranberg K., Grandjean P. Low activity of superoxide dismutase and high activity of glutathione reductase in erythrocytes from centenarians. Age Ageing 1998, 27:634-648.
51. Liu Q., Xie F., Rolston R., Moreira P.I., Nunomura A., Zhu X., Smith M.A., Perry G. Prevention and treatment of Alzheimer Disease and aging: antioxidants. Mini-Rev. Med. Chem. 2007, 7:171-180.
52. Masters C.L., Beyreuther K. Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the β-amyloid pathway. Brain 2006, 129:2823-2839.
53. Choi S.H., Bosetti F. Cyclooxygenase-1 nullmice show reduced neuroinflammation in response to beta-amyloid. Aging (Albany NY) 2009, 1:234-244.
54. McLachlan C., Dalton A.J., Kruck T.P., Bell M.Y., Smith W.L., Kalow W., Andrews D.F. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991, 337:1304-1308.
55. Sohal R.S., Weindruch R. Oxidative stress, caloric restriction, and aging. Science 1996, 273:59-63.
56. Mayeux R., Sano M. Treatment of Alzheimer's disease. N. Engl. J. Med. 1999, 341:1670-1679.
57. Luchsinger J.A., Noble J.M., Scarmeas N. Diet and Alzheimer's Disease. Curr. Neurol. Neurosci. Rep. 2007, 7:366-372.
58. Navrátilová M., Jarkovsky J., Ceßková E., Leonard B., Sobotka L. Alzheimer disease: malnutrition and nutritional suport. Clin. Exp. Pharmacol. Physiol. 2007, 34:S11-S13.
59. Navarro-Meza M., Gabriel-Ortiz G., Pacheco-Moisés F.P., Cruz-Ramos J.A., López-Espinoza A. Dietary fat and antioxidant vitamin intake in patients of neurodegenerative disease in a rural region of Jalisco, Mexico. Nutr. Neurosci. 2014, 17:260-267.
60. Luchsinger J.A., Tang M.-X., Shea S., Mayeux R. Caloric intake and the risk of Alzheimer disease. Arch. Neurol. 2002, 59:1258-1263.
61. Aliev G., Obrenovich M.E., Reddy V.P., Shenk J.C., Moreira P.I., Nunomura A., Zhu X., Smith M.A., Perry G. Antioxidant therapy in Alzheimer's disease: theory and practice. Mini-Rev. Med. Chem. 2008, 8:1395-1406.
62. Harris M.E., Hensley K., Butterfield D.A., Leedle R.A., Carney J.M. Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. 1995, 131:193-202.
63. Rota C., Rimbach G., Minihane A.M., Stoecklin E., Barella L. Dietary vitamin E modulates differential gene expression in the rat hippocampus: potential implications for its neuroprotective properties. Nutr. Neurosci. 2005, 8:21-29.
64. Sung S., Yao Y., Uryu K., Yang H., Lee V.M., Trojanowski J.Q., Pratico D. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J. 2004, 18:323-325.
65. Perkins A.J., Hendrie H.C., Callahan C.M., Gao S., Unverzagt F.W., Xu Y., Hall K.S., Hui S.L. Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. Am. J. Epidemiol. 1999, 150:37-44.
66. Morris D.A., Evans J.L., Tangney J.L.C.C., Wilson R.S. Vitamin E and cognitive decline in older persons. Arch. Neurol. 2002, 59:1125-1132.
67. Choi J., Conrad C.C., Dai R., Malakowsky C.A., Talent J.M., Carroll C.A., Weintraub S.T., Gracy R.W. Vitamin E prevents oxidation of antiapoptotic proteins in neuronal cells. Proteomics 2003, 3:73-77.
68. Engelhart M.J., Geerlings M.I., Ruitenberg A., van Swieten J.C., Hofman A., Wittman J.C., Breteler M.M. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002, 287:3223-3229.
69. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennett D.A., Aggarwal N., et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002, 287:3230-3237.
70. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., et al. A controlled trial of seligiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N. Engl. J. Med. 1997, 336:1216-1222.
71. Petersen R.C., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., et al. Vitamin E and donezepil for the treatment of mild cognitive impairment. N. Engl. J. Med. 2005, 352:2379-2388.
72. Jack C.R., Petersen R.C., Grundman M., Jin S., Garnst A., Ward C.P. Longitudinal MRI findings from the vitamin E and donezepil treatment study for MCI. Neurobiol. Aging 2007, 29:1285-1295.
73. Luchsinger J.A., Tang M.X., Shea S., Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch. Neurol. 2003, 60:203-208.
74. Zandi P.P., Anthony J.C., Khachaturian A.S., Stone S.V., Gustafson D., Tschanz J.T., et al. Reduced risk of Alzheimer disease in users of antioxidants vitamin supplements: the Cache County Study. Arch. Neurol. 2004, 61:82-88.
75. Usoro O.B., Mousa S.A. Vitamin E forms in Alzheimer's disease: a review of controversial and clinical experiences. Crit. Rev. Food Sci. Nutr. 2010, 50:414-419.
76. Moreira P.I., Honda K., Liu Q., Santos M.S., Oliveira C.R., Aliev G., Nunomura A., Zhu X., Smith M.A., Perry G. Oxidative stress: the old enemy in Alzheimer's disease pathophysiology. Curr. Alzheimer Res. 2005, 2:403-408.
77. Chava B., Pocernich D., Butterfield A. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim. Biophys. Acta 2012, 1822:625-630.
78. Nuttall S.L., Martin U., Sinclair A.J., Kendall M.J. Glutathione: in sickness and in health. Lancet 1998, 351:645-646.
79. Portet F., Ousset P.J., Touchon J. What is a mild cognitive impairment?. Rev. Prat. 2005, 55:1891-1894.
80. Baldeiras I., Santana I., Proenca M.T., Garrucho M.H., Pascoal R., Rodrigues A., Duro D., Oliveira C.R. Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. J. Alzheimers Dis. 2008, 15:117-128.
81. Pocernich C.B., La Fontaine M., Butterfield D.A. In-vivo glutathione elevation protects against hydroxyl free radical-induced protein oxidation in rat brain. Neurochem. Int. 2000, 36:185-191.
82. Farr S.A., Poon H.F., Dogrukol-Ak D., Drake J., Banks W.A., Eyerman E., Butterfield D.A., Morley J.E. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J. Neurochem. 2003, 84:1173-1183.
83. LaFontaine M.A., Geddes J.W., Butterfield D.A. 3-nitropropionic acid-induced changes in bilayer fluidity in synaptosomal membranes: implications for Huntington's disease. Neurochem. Res. 2002, 27:507-511.
84. Zhang Q., Tian H., Fu X., Zhang G. Delayed activation and regulation of MKK7 in hippocampal CA1 region following global cerebral ischemia in rats. Life Sci. 2003, 74:37-45.
85. Fu A.L., Dong Z.H., Sun M.J. Protective effect of N-acetyl-l-cysteine on amyloid beta-peptide-induced learning and memory deficits in mice. Brain Res. 2006, 1109:201-206.
86. Huang Q., Aluise C.D., Joshi G., Sultana R., St Clair D.K., Markesbery W.R., Butterfield D.A. Potential in vivo amelioration by N-acetyl-l-cysteine of oxidative stress in brain in human doublemutant APP/PS-knock-inmice: toward therapeuticmodulation of mild cognitive impairment. J. Neurosci. Res. 2010, 88:2618-2629.
87. Fuller S., Steele M., Munch G. Activated astroglia during chronic inflammation in Alzheimer's disease-do they neglect their neurosupportive roles?. Mutat. Res. 2010, 690:40-49.
88. Pahan K., Sheikh F.G., Namboodiri A.M., Singh I. N-acetyl cysteine inhibits induction of no production by endotoxin or cytokine stimulated rat peritoneal macrophages, C6 glial cells and astrocytes. Free Radic. Biol. Med. 1998, 24:39-48.
89. Adair J.C., Knoefel J.E., Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 2001, 57:1515-1517.
90. Drake J., Sultana R., Aksenova M., Calabrese V., Butterfield D.A. Elevation of mitochondrial glutathione by gamma-glutamylcysteine ethyl ester protects mitochondria against peroxynitrite-induced oxidative stress. J. Neurosci. Res. 2003, 74:917-927.
91. Boyd-Kimball D., Sultana R., Abdul H.M., Butterfield D.A. Gamma-glutamylcysteine ethyl ester-induced up-regulation of glutathione protects neurons against Abeta(1-42)-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J. Neurosci. Res. 2005, 79:700-706.
92. Frank B., Gupta S.A. A review of antioxidants and Alzheimer's disease. Ann. Clin. Psychiatry 2005, 17:269-286.
93. Teixeira J., Silva T., Andrade P.B., Borges F. Alzheimer's Disease and antioxidant therapy: how long how far?. Curr. Med. Chem. 2013, 20:2939-2952.
94. Mecocci P., Polidori M.C. Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochim. Biophys. Acta 2012, 1822:631-638.
95. Wadsworth T.L., Bishop J.A., Pappu A.S., Woltjer R.L., Quinn J.F. Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease. J. Alzheimers Dis. 2008, 14:225-234.
96. Bonda D.J., Lee H.P., Lee H.G., Friedlich A.L., Perry G., Zhu X., Smith M.A. Novel therapeutics for Alzheimer's disease: an update. Curr. Opin. Drug Discov. Dev. 2010, 13:235-246.
97. Morillas-Ruiz J.M., Rubio-Perez J.M., Albaladejo M.D., Zafrilla P., Parra S., Vidal-Guevara M.L. Effect of an antioxidant drink on homocysteine levels in Alzheimer's patients. J. Neurol. Sci. 2009, 299:175-178.
98. Morris M.S. Homocysteine and Alzheimer's disease. Lancet. Neurol. 2003, 7:425-428.
99. Dai Q., Borenstein A.R., Wu Y., Jackson J.C., Larson E.B. Fruit and vegetable juices and Alzheimer's disease: the Kame Project. Am. J. Med. 2006, 119:751-759.
100. Wang J., Zhao Z., Ho L., Seror I., Humala N., Percival S., et al. Moderate consumption of Cabernet Sauvignon attenuates β-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J. 2006, 20:2313-2320.
101. Luchsinger J.A., Tang M.-X., Siddiqui M., Shea S., Mayeux R. Alcohol intake and risk of dementia. J. Am. Geriatr. Soc. 2004, 52:540-546.
102. Shi S., Zhao X., Liu A., Liua B., Li H., Wua B., Bi K., Jia Y. Protective effect of n-butanol extract from Alpinia oxyphylla on learning and memory impairments. Physiol. Behav. 2005, 139:13-20.
103. Liu A., Zhao X., Li H., Liu Z., Liu B., Mao X., Guo L., Bi K., Jia Y. 5-Hydroxymethylfurfural, an antioxidant agent from Alpinia oxyphylla Miq. improves cognitive impairment in Aβ1-42 mouse model of Alzheimer's disease. Int. Immunipharmacol. 2014, 23:719-725.
104. Mancuso C., Siciliano R., Barone E., Preziosi P. Natural substances and Alzheimer's disease: From preclinical studies to evidence based medicine. BBA 2012, 1822:616-624.
105. Bridi R., Crossetti F.P., Steffen V.M., Henriques A.T. The antioxidant activity of standardized extract of Ginkgo biloba (EGb 761) in rats. Phytother Res. 2001, 15:449-451.
106. Shi C., Liu J., Wu F., Yew D.T. Ginkgo biloba extract in Alzheimer's disease: from action mechanisms to medical practice. Int. J. Mol. Sci. 2010, 11:107-123.
107. Luo Y., Smith J.V., Paramasivam V., Burdick A., Curry K.J., Buford J.P., Khan I., Netzer W.J., Xu H., Butko P. Inhibition of amyloid-beta aggregation and caspase-activation by the Ginkgo biloba extract EGb761. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:12197-12202.
108. Bastianetto S., Ramassamy C., Dore S., Christen Y., Poirier J., Quirion R. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur. J. Neurosci. 2000, 12:1882-1890.
109. Stackman R.W., Eckenstein F., Frei B., Kulhanek D., Nowlin J., Quinn J.F. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp. Neurol. 2003, 184:510-520.
110. Bastianetto S., Zheng W.H., Quirion R. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents and protein kinase C. J. Neurochem. 2000, 74:2268-2277.
111. Smith J.V., Luo Y. Elevation of oxidative free radicals in Alzheimer's disease models can be attenuated by Ginkgo biloba extract EGb 761. J. Alzheimers Dis. 2003, 5:287-300.
112. Le Bars P.L., Kieser M., Itil K.Z. A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761 in dementia. Dement. Geriatr. Cogn. Disord. 2000, 11:230-237.
113. Kanowski S., Hoerr R. Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 2003, 36:297-303.
114. Schneider L.S., DeKosky S.T., Farlow M.R., Tariot P.N., Hoerr R., Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr. Alzheimer Res. 2005, 2:541-551.
115. DeKosky S.T., Williamson J.D., Fitzpatrick A.L., Kronmal R.A., Ives D.G., Saxton J.A., Lopez O.L., Burke G., Carlson M.C., Fried L.P., Kuller L.H., Robbins J.A., Tracy R.P., Woolard N.F., Dunn L., Snitz B.E., Nahin R.L., Furberg C.D. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008, 300:2253-2262.
116. Snitz B.E., O'Meara E.S., Carlson M.C., Arnold A.M., Ives D.G., Rapp S.R., Saxton J., Lopez O.L., Dunn L.O., Sink K.M., DeKosky S.T. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 2009, 302:2663-2670.
117. Weinmann S., Roll S., Schwarzbach C., Vauth C., Willich S.N. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr. 2010, 10:14.
118. Prasanthi J.R.P., Dasari B., Marwarha G., et al. Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterolenriched diet. Free Radic. Biol. Med. 2010, 49:1212-1220.
119. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic Mouse. J. Neurosci. 2001, 21:8370-8377.
120. Lu P., Mamiya T., Lu L.L., et al. Silibinin prevents amyloid beta peptide-induced memory impairment and oxidative stress in mice. Br. J. Pharmacol. 2009, 157:1270-1277.
121. Manczak M., Mao P., Calkins M., et al. Mitochondriatargeted antioxidants protects against Abeta toxicity in Alzheimer's disease neurons. J. Alzheimer Dis. 2010, 20:S609-S631.
122. Tuppo E.E., Forman L.J. Free radical oxidative damage and Alzheimer's disease. J. Am. Osteopath. Assoc. 2001, 101:S11-S15.
123. Feng Z., Zhang J.T. Protective effect of melatonin on β-amyloid-induced apoptosis in rat astroglioma c6 cells and its mechanism. Free Radic. Biol. Med. 2004, 37:1790-1801.
124. Matsubara E., Bryant-Thomas T., Quinto J.P., et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J. Naurochem. 2003, 85:1101-1108.
125. Quinn J., Kulhanek D., Nowlin J., et al. Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Res. 2005, 1037:209-213.
126. Knapp M.J., Knopman D.S., Solomon P.R., Pendlebury W.W., Davis C.S., Gracon S.I. A 30-week randomized controlled trial of high-dose tacrine in patientswith Alzheimer's disease. The Tacrine study group. JAMA 1994, 271:985-991.
127. Custódio L., Patarra J., Alberício F., da Rosa Neng N., Nogueira J.M.F., Romano A. Phenolic composition, antioxidant potential and in vitro inhibitoryactivity of leaves and acorns of Quercus suber on key enzymes relevantfor hyperglycemia and Alzheimer's disease. Ind. Crop Prod. 2015, 64:45-51.
128. Kamal Z., Ullah F., Ayaz M., Sadiq A., Ahmad S., Zeb A., Hussain A., Imran M. Anticholinesterse and antioxidant investigations of crude extracts, subsequent fractions, saponins and flavonoids of Atriplex laciniata L.: potential effectiveness in Alzheimer's and other neurological disorders. Biol. Res. 2015, 48:1-11.
129. Dhanasekaran S., Perumal P., Palayan M. In-vitro Screening for acetylcholinesterase enzyme inhibition potential and antioxidant activity of extracts of Ipomoea aquatica Forsk: therapeutic lead for Alzheimer's disease. JAPS 2015, 5:12-16.
130. Zhang X.D., Liu X.Q., Kim Y.H., Whang W.K. Chemical constituents and their acetyl cholinesterase inhibitory and antioxidant activities from leaves of Acanthopanax henryi: potential complementary source against Alzheimer's disease. Arch. Pharm. Res. 2014, 37:606-616.
131. Asaduzzaman M., Uddin M.J., Kader M.A., Alam A.H.M.K., Rahman A.A., Rashid M., Kato K., Tanaka T., Takeda M., Sadik G. In vitro acetylcholinesterase inhibitory activity and the antioxidant properties of Aegle marmelos leaf extract: implications for the treatment of Alzheimer's disease. Psychogeriatrics 2014, 14:1-10.
132. Bonesi M., Loizzo M.R., Conforti F., Passalacqua N.G., Saab A., Menichini F., Tundis R. Berberis aetnensis and B. libanotica: a comparative study on the chemical composition, inhibitory effect on key enzymes linked to Alzheimer's disease and antioxidant activity. J. Pharmacol. 2013, 65:1726-1735.
133. Garciía-Morales G., Huerta-Reyes M., González-Cortazar M., Zamilpa A., Jiménez-Ferrer E., Silva-García R., Román-Ramos R., Aguilar-Rojas A. Anti-inflammatory, antioxidant and anti-acetylcholinesterase activities of Bouvardia ternifolia: potential implications in Alzheimer's disease. Arch. Pharm. Res. 2015, 38:1369-1379.
134. Alama B., Haque E. Anti-Alzheimer and Antioxidant Activity of Celastrus paniculatus Seed. Indian J. Pharm. Sci. 2010, 7:49-56.
135. Thaipisuttikul P., Galvin J.E. Use of medical foods and nutritional approaches in the treatment of Alzheimer's disease. Clin. Pract. 2012, 9:199-209.
136. Oniszczuk A., Podgórski R., Oniszczuk T., Zukiewicz-Sobczak W., Nowak R., Waksmundzka-Hajnos M. Extraction methods for the determination of phenolic compounds from Equisetum arvense L. herb. Ind. Crop. Prod. 2014, 61:377-381. 61.
137. Oniszczuk A., Wójtowicz A., Oniszczuk T., Olech M., Nowak R., Wojtunik K., Klimek M., Krawczyk W., Hajnos M. Extruded corn gruels containing linden flowers: quantitation of phenolic compounds and selected quality characteristics. Open Chem. 2015, 13:1209-1217.
138. Swaminathan A., Jicha G.A. Nutrition and prevention of Alzheimer's dementia. Front. Aging Neurosci. 2014, 6:1-13.
139. Feng Y., Wang X. Antioxidant therapies for Alzheimer's disease. Oxid. Med. Cell. Longev. 2012, ID 472932.